Generation Bio to Present at the Jefferies Virtual Healthcare Conference
Get Alerts GBIO Hot Sheet
Join SI Premium – FREE
CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, at 11:30 a.m. ET.
A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.
About Generation Bio
Generation Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is designed to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company’s efficient, scalable manufacturing process supports Generation Bio’s mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.
For more information, please visit www.generationbio.com.
Contact:
Investors
Maren Killackey
Generation Bio
[email protected]
541-646-2420
Media
Alicia Webb
Generation Bio
[email protected]
847-254-4275
Stephanie Simon
Ten Bridge Communications
[email protected]
617-581-9333
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
- LingoPlus Expands Nationwide: Certified Translation Services Now Available Across Germany
- As U.S. Markets Power to Historic All-Time Highs, Reminiscent of the Dot-Com Boom Era, ELEKTROS Inc. Celebrates a 10% Friday Gain While Advancing a Bold Long-Term Vision for Shareholders
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share